Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 1/20 | 0.36 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22917015 | 0.82 | KCNJ1 (0.40) | ERCC1ERCC4ANPEP | |
| SCHEMBL22861720 | 0.78 | GBA1 (0.44) | ANPEP | |
| SCHEMBL19655507 | 0.78 | ANPEP (0.41) | ERCC1ERCC4ANPEP | |
| SCHEMBL22733285 | 0.75 | ANPEP (0.40) | ERCC1ERCC4ANPEP | |
| SCHEMBL12573853 | 0.74 | ANPEP (0.43) | ANPEP | |
| SCHEMBL13311678 | 0.74 | MMP2 (0.43) | ANPEP | |
| SCHEMBL23568346 | 0.73 | GLS (0.41) | ANPEP | |
| SCHEMBL21106552 | 0.72 | ADRB2 (0.44) | ANPEP | |
| SCHEMBL23945435 | 0.71 | GBA1 (0.41) | ANPEP | |
| SCHEMBL25477544 | 0.70 | GLS (0.39) | ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11077198-B2 | Pegylated carfilzomib compounds | AMGEN INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20200376131-A1 | Pegylated Carfilzomib Compounds | AMGEN INC. (US) | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200376131-A1 | Pegylated Carfilzomib Compounds | FCGRT, EPOR, MCL1 | ERCC1 3413/4885ERCC4 3385/4885ANPEP 336/4885 |
| US-11077198-B2 | Pegylated carfilzomib compounds | FCGRT, EPOR, MCL1 | ERCC1 3413/4885ERCC4 3385/4885ANPEP 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.